Company
Mountain Valley MD Holdings Inc
CNSX:MVMD
Mountain Valley MD Holdings Inc (CSE:MVMD) (OTCMKTS:MVMD) is building a world-class biotech and life sciences company centered around the implementation of its patented Quicksome oral drug formulation and delivery technologies. The company applies its Quicksome desiccation technology towards the oral delivery of vaccines and pharmaceutical drugs as well as the development of products for pain management, weight loss, energy, focus, sleep and anxiety. It is also looking at the fight against the coronavirus (COVID-19). Quicksome enables unprecedented delivery impact through sublingual and buccal formats that provide direct absorption into the bloodstream, dramatically improving drug efficacy, dosing and end-user experience. The result is a new generation of product formulations that are capable of delivering vaccines, drugs and nutraceuticals into the body faster, with greater impact, efficiency and accuracy. The Quicksome technology has been in development since 2010, and initially incorporated into several commercial dietary supplement products. To date, the company has 14 patents in its portfolio, 12 extensions and has filed over a dozen provisional patents with respect to its Quicksome technology.
42 stories
Mountain Valley MD kicks off commercial sales of Agrarius, an agro plant technology
"Leveraging science to help eliminate harmful pesticides and chemicals often associated with agricultural practices is very aligned with our mission," said MVMD CEO Dennis Hancock
Mountain Valley MD's parasite treatment Soluvec beats ivermectin in pre-clinical pharmacokinetic study
The study tested intramuscular (IM) and subcutaneous (SC) dosing of Soluvec 1% against oral administration of ivermectin in male beagle dogs
Mountain Valley MD updates on its technologies and pre-clinical progress across broad husbandry animal and human applications
The company sees “significant potential” in treating mycobacterium-based infections in humans and animals with its solubilized format of Selactosol 1.5% and it plans to start pre-clinical studies with the drug in the “latter half of 2022”
Mountain Valley MD welcome immunologist Elizabeth Norton to an advisory position for supporting its key Quicksome vaccine
Norton is an immunologist with 20 years of experience in evaluating immunity, vaccines, and microbial infections
Mountain Valley MD looking to eradicate needles with its patented Quicksome oral drug delivery technology
Quicksome enables unprecedented delivery impact through sublingual and buccal formats that provide direct absorption into the bloodstream, dramatically improving drug efficacy, dosing and end-user experience
Mountain Valley MD Holdings completes licensing agreement with Red White and Bloom Brands
CEO Dennis Hancock said the partnership with Red White & Bloom shows how Mountain Valley’s Quicksome “technology can support product innovation objectives for our key partners across a variety of market verticals”
Mountain Valley MD updates on pre-clinical progress across broad husbandry animal and human applications
The firm is developing therapies and technologies for the global pharmaceutical and nutraceutical industries
Mountain Valley MD enters into a letter of intent to complete a licensing agreement with Red White & Bloom Brands
The two companies expect to complete a product development and commercial licensing agreement before the end of October, setting out the terms under which Mountain Valley will develop one or more formulas using its Quicksome technology and
NA Proactive news snapshot: Cloud DX, Playgon Games, LQwD Fintech, Dalrada Corporation UPDATE ...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Mountain Valley MD stock uplists to the OTCQX Best Market as it eyes US senior exchange listing
Mountain Valley MD shares will begin trading on the OTCQX Best Market under the symbol ‘MVMDF’ effective August 27, 2021
Mountain Valley MD announces appointment of Dr Azhar Rana as the company’s chief medical officer
Dr Rana brings to the company nearly two decades of life sciences experience in clinical development, pre and post-launch medical affairs, regulatory and commercial strategy, including 10 years of pharmaceutical leadership at Bristol Myers-
Mountain Valley MD Holdings appoints Gokul Kannan and Mark Gelnaw as new advisors and updates on listing plans
"I am extremely proud to welcome Gokul and Mark to our Advisory Board at Mountain Valley MD and look forward to their immediate contributions at this critical growth phase of our company," said Dennis Hancock, the CEO of Mountain Valley MD
Mountain Valley MD Holdings says its Quicksome technology could change vaccine landscape after cold chain tests
The World Health Organization (WHO) estimates that more than 50% of vaccines are wasted globally every year due to temperature control and logistics
Mountain Valley MD updates on recent key initiatives, including award of 'cornerstone' patent
Dennis Hancock, Mountain Valley MD CEO, said the patent would allow the group "to move forward in securing the global protections necessary across many human and animal health applications without competitive interference"
Mountain Valley MD Holdings hails Ivectosol lab study results on COVID-19 variants
The BSL-4 study was the first of its kind ever conducted with human grade solubilized Ivermectin in the world
Mountain Valley MD Holdings updates on "encouraging" progress in its pre-clinical trial portfolio
The Canadian company is focused on the implementation of its patented Quicksome oral drug formulation and delivery technologies and its Quicksol solubilization technology
Mountain Valley MD CEO thinks investors should be excited about the company’s ability to bring technology into commercialization this year
The company is focused on the oral delivery of vaccines and pharmaceutical drugs as well as the development of products for pain management, weight loss, energy, focus, sleep and anxiety
Mountain Valley MD says it has filed a novel cancer adjuvant patent and is proceeding with pre-clinical trials
The company said the cancer patent has been filed for direct intratumoral injection, intravenously, infusions or instillations as adjuvants for broad chemotherapeutic to immunotherapeutic cancer regimens
Mountain Valley MD proceeds with pre-clinical cancer trials and files a related cancer patent
The company said ivectosol is being tested to target certain cancers to pursue novel human intratumoral injection and intravenous infusion
Mountain Valley MD to file application for listing on the Toronto Venture Exchange this week
The biotechnology company’s board of directors has approved the move
Mountain Valley MD to start husbandry animal trials of Ivectosol 1% technology in Bangladesh
The company is finalizing production supply agreements with Bangladeshi pharmaceutical partners to produce Ivectosol 1% for use and distribution throughout the country
Mountain Valley MD achieves a water solubilized selamectin product using its Quicksol technology
Selamectin was once considered a water-insoluble molecule but with tremendous potential in treating parasitic infestations in husbandry and companion animals as well as buruli ulcer, leprosy, and tuberculosis in humans
Mountain Valley MD Holdings brings on Camargo Pharmaceutical Services to boost US FDA approval for Ivectsol
Mountain Valley MD told investors that it believes the 505(b)(2) pathway will result in a much less expensive and much faster route to approval
Mountain Valley MD Holdings poised for animal trials on its Ivectosol 1% solution
Husbandry animal trials are set to start with a third-party preclinical contract research organization (CRO)
Mountain Valley MD sees its first revenue via deal with Circadian Wellness for Quicksome technology
The agreement to apply Quicksome technology to mushroom neutraceutical products includes ongoing product royalties and an initial payment of C$250,000
Mountain Valley MD adds South African coronavirus variant to upcoming viral clearance study of solubilized Ivermectin technology
CEO Dennis Hancock said it was “critical” to look at the new South African variant given the complexities of vaccine rollout and the high probability that current vaccines may not be effective against emerging mutations
Mountain Valley MD names Tulane University School of Medicine as its CRO for its inactivated polio vaccine study
The move marks another step toward achieving the global eradication of polio, the biotech said
Mountain Valley MD inks agreement to begin its coronavirus viral clearance study
The company said the study is designed to prove the superiority of its solubilized Ivermectin technology versus a commercially available oral form in speed and efficacy of viral clearance
Mountain Valley MD files patent for aluminum adjuvant process to get more bang for your buck out of vaccines
Adjuvants improve the immune response of a vaccine, enabling vaccines to produce more antibodies and achieve longer-lasting immunity, thus allowing for lower dosage
Mountain Valley MD says it has received approval from the Canadian Intellectual Property Office for the patent filing around its Quicksome technology
The company's patented Quicksome liposome technology utilizes an advanced two-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective oral product formats
Mountain Valley MD submits application to list on the OTCQB market in New York
The listing of its common shares on the OTCQB, a platform operated by OTC Markets Group, remains subject to the exchange's approval and satisfaction of applicable listing requirements
Mountain Valley MD says it has completed first portion of a multiprong strategic agreement with Circadian Wellness
The company said it has completed the previously announced transaction to sell its wholly-owned subsidiary, Mountain Valley Medicinals Inc. and its related assets for the amount of C$1,000,000, made up of a combination of cash and a 9% equi
Mountain Valley MD files for accelerated review of its macrocyclic lactone solubilization patent with the United States Patent and Trademark Office
To support the accelerated patent examination request, the company said it has provided the patent office with new formulation analyses of different diluted concentrations of its Quicksol Ivermectin in solution
Mountain Valley MD brings in over $4.3M in oversubscribed private placement to advance pre-clinical trials
CEO Dennis Hancock said that while making presentations over the past few weeks the firm identified strategic biotech and pharma investors and brought some "significant partners into the fold"